Watch the interview with the CEO Fredrik Lindblad below.
BiBBInstruments: “The goal is to have an agreement before the summer holidays”
The reporting season is in full swing and BiBBInstruments has now reported its first quarter for 2025. BioStock met with CEO Fredrik Lindblad to talk about the quarterly report and the ongoing commercialization preparations. In the interview, Lindblad discusses, among other things, the work to scale up the manufacturing and reception of EndoDrill in clinics in the US and Europe. He also shares his thoughts on the first step into the commercial phase and the timeline for an official launch.
Notes
Cantargia publishes data for nadunolimab in lung cancer
Genmab reports sales of DARZALEX
AlzeCure receives additional subscription commitments of SEK 7 million
AstraZeneca updates on phase III study
Orexo maintains full-year forecast despite currency headwinds
NEWSLETTER
NEWS
Biovica's blood test provides new answers for cancer care
Green light for PHI to step up its commercial strategy
Enzymatica's CEO comments on his resignation
Upcoming events!
Investing in Life Science
Discover unparalleled opportunities, set in the vibrant heart of Stockholm. This premier event unites forward-thinking investors and business leaders to...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The market is taking Trump's tariff threat in stride
The EU's new life science strategy – a step in the right direction or just fluff?
